<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is the association between <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> and pregnancy morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>Although the kidney may be affected in APS, the treatment of renal involvement is yet to be elucidated </plain></SENT>
<SENT sid="2" pm="."><plain>This report describes the clinical and laboratory features of four patients with primary APS <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and the beneficial effect of immunosuppressive therapy accompanied by <z:chebi fb="8" ids="10033">warfarin</z:chebi> and <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We also briefly discuss the possible mechanisms of the beneficial effects of immunosuppressives on primary APS <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>